Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy Subjects
A PhaseⅠRandomised, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Characteristics of the Oral Topical Use of GB001 Recombinant Peptide Spray in Chinese Healthy Adult Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- The First Affiliated Hospital of Nanjing Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy males or females aged 18 to 45 years, with a body mass index(BMI) 19-26kg/m2 and body weight no less than 45 kg (female) or 50 kg (male).
- The results in the screening examinations (including general physical examination, vital signs, laboratory examinations, electrocardiogram, chest radiograph, etc.) are in the normal range, or are abnormal without clinical significance assessed by the investigator.
- Subjects and their sexual partners agree to take effective contraceptive measures during the study period and at least 3 days after the end of the study.
- Understanding and willing to comply strictly with the clinical trial protocol, complete all test procedures required in this trial, understand and sign informed consent form.
Exclusion Criteria:
- Those allergic to GB001 peptide or any other drugs, or suffered from allergic disease or allergic constitution.
- Any obvious clinical symptoms or abnormal test results with clinical significance suggested organ or system illness, unsuitable for inclusion in this trial in the investigator's judgement.
- Subjects has obvious oral lesions or diseases, such as erosion of oral mucosa, ulcer or obvious periodontitis.
- The weekly alcohol intake in 90 days before screening is more than 21 units (male) and more than 14 units (female) , or the subject is unwilling to stop drinking whenever required for the trial procedure.
- Subject who smoke more than 10 cigarettes per day or is unwilling to stop smoking whenever required for the trial procedure.
- Subject with a history of drug abuse, or those with positive urine screening test for drug abuse.
- Subject who use of any other drugs within 30 days prior to screening, including prescription drugs, non-prescription drugs, biologicals, vitamins, minerals and nutritional supplements.
- Blood loss or blood donation more than 400 mL within 90 days prior to screening.
- Received major surgery within 90 days prior to screening, or participated in any other drug/device clinical trial.
- Pregnant or lactating women; or female subject of childbearing age have a positive serum pregnancy test result during the screening.
- Subject with dizzy needle or difficulty in venous blood collection.
- Subject unsuitable for the trial in the judgement of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Single dose-escalation of GB001 recombinant peptide spray
Each subject will receive one single administration of GB001 recombinant peptide.
The dosage of each group is 0.054mg, 0.108mg, 0.216mg, 0.432mg and 0.864mg, respectively.
|
administrated oral spray
administrated oral spray
|
|
Experimental: Oral retention time test for a single dose
Each subject will receive one single administration of GB001 recombinant peptide.
The dosage of the group is 0.108mg.
|
administrated oral spray
|
|
Experimental: Multiple Ascending Dose of GB001 recombinant peptide spray
Each subject will be dosed with oral spray of GB001 recombinant peptide ten times per day for four days.
GB001 recombinant peptide will be administrated, and the dosage of each group is 0.108mg, 0.216mg and 0.432mg, respectively.
|
administrated oral spray
administrated oral spray
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events
Time Frame: Through the study completion, an average of 2 weeks
|
The number and the incidence of serious and non-serious adverse events observed in each treatment will be used to assess the safety and tolerability
|
Through the study completion, an average of 2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics Characteristics, t½ of GB001 recombinant peptide
Time Frame: Up to 240 minutes after last dose
|
Apparent terminal phase half-life
|
Up to 240 minutes after last dose
|
|
Pharmacokinetics Characteristics , Cmax of GB001 recombinant peptide
Time Frame: Up to 240 minutes after last dose
|
Maximum plasma concentration
|
Up to 240 minutes after last dose
|
|
Pharmacokinetics Characteristics , Tmax of GB001 recombinant peptide
Time Frame: Up to 240 minutes after last dose
|
Time of maximum plasma concentration
|
Up to 240 minutes after last dose
|
|
Pharmacokinetics Characteristics , AUC of GB001 recombinant peptide
Time Frame: Up to 240 minutes after last dose
|
Area under the plasma concentration versus time curve
|
Up to 240 minutes after last dose
|
|
Pharmacokinetics Characteristics , Vd of GB001 recombinant peptide
Time Frame: Up to 240 minutes after last dose
|
Apparent distribution volume
|
Up to 240 minutes after last dose
|
|
Pharmacokinetics Characteristics , Ctrough of GB001 recombinant peptide
Time Frame: Up to 240 minutes after last dose
|
Trough plasma concentration
|
Up to 240 minutes after last dose
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oral retention time
Time Frame: Up to 120 minute after first dose
|
Oral retention time
|
Up to 120 minute after first dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Feng Shao, MD, The First Affiliated Hospital with Nanjing Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- YK2019L01P-Ⅰ
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.